← Leaderboards
Brian L Sprague
University Of Vermont & St Agric College
$10,667,519
Attributed
$17,045,595
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,451,257 · 11
By mechanism
U54$10,154,094 · 6
R01$6,744,190 · 2
U01$5,391,498 · 1
P20$989,365 · 1
R03$172,110 · 1
Top collaborators
- Donald Lee Weaver11 shared
- Janet L Stein7 shared
- Natasha Kay Stout4 shared
- Emily Conant2 shared
- Diana L Miglioretti1 shared
Most similar at University Of Vermont & St Agric College
Same institution · by research overlap
- Emily Conant$86,055
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanMalignant Breast NeoplasmMalignant NeoplasmsBreast Cancer DetectionNoninfiltrating Intraductal CarcinomaPathologyVermontLeadUnited StatesRadiology SpecialtyLifePopulation BasedBreastRisk FactorsCancer TherapyScreeningSiteMammographyRegistriesBreast Cancer DiagnosisMultidisciplinaryBreast ImagingStagingGuidelines
Grant awards (47)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis$829,068
R01 · FY2025 · CA · contact PI
Evaluation of risk-based supplemental ultrasound and MRI screening strategies for women with dense breasts$777,725
R01 · FY2025 · CA · contact PI
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts$707,023
R01 · FY2024 · CA · contact PI
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis$686,647
R01 · FY2024 · CA · contact PI
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis$840,327
R01 · FY2023 · CA · contact PI
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts$641,789
R01 · FY2023 · CA · contact PI
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts$649,400
R01 · FY2022 · CA · contact PI
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts$674,979
R01 · FY2021 · CA · contact PI
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts$757,232
R01 · FY2020 · CA · contact PI
Vermont Breast Cancer Molecular Characterization Laboratory$587,560
U01 · FY2020 · CA
Estimating the impact of mammography screening disruptions during the COVID-19 pandemic$180,000
R01 · FY2020 · CA · contact PI
Vermont Breast Cancer Molecular Characterization Laboratory$1,167,066
U01 · FY2019 · CA
Multi-center evaluation of digital breast tomosynthesis with synthesized two-dimensional mammography for breast cancer screening$79,055
R03 · FY2019 · CA · contact PI
Vermont Breast Cancer Molecular Characterization Laboratory$1,053,429
U01 · FY2018 · CA
Multi-center evaluation of digital breast tomosynthesis with synthesized two-dimensional mammography for breast cancer screening$93,055
R03 · FY2018 · CA · contact PI
Vermont Breast Cancer Molecular Characterization Laboratory$741,335
U01 · FY2017 · CA
Vermont PROSPR Research Center (VPRC)$608,939
U54 · FY2017 · CA · contact PI
Vermont Breast Cancer Molecular Characterization Laboratory$312,000
U01 · FY2017 · CA
Behaviors, Chronic Disease, and Quality of Life After Ductal Carcinoma in Situ$160,692
P20 · FY2017 · GM · contact PI
Vermont Breast Cancer Molecular Characterization Laboratory$812,868
U01 · FY2016 · CA
Behaviors, Chronic Disease, and Quality of Life After Ductal Carcinoma in Situ$194,018
P20 · FY2016 · GM · contact PI
Vermont PROSPR Research Center (VPRC)$60,149
U54 · FY2016 · CA · contact PI
Vermont PROSPR Research Center (VPRC)$1,072,210
U54 · FY2015 · CA · contact PI
Vermont Breast Cancer Molecular Characterization Laboratory$717,240
U01 · FY2015 · CA
Vermont Screening Process Documentation Unit$469,642
U54 · FY2015 · CA · contact PI
Behaviors, Chronic Disease, and Quality of Life After Ductal Carcinoma in Situ$194,018
P20 · FY2015 · GM · contact PI
Vermont Administrative Core$138,449
U54 · FY2015 · CA · contact PI
Breast density and collagen alignment as predictors of DClS disease-free survival$102,129
U54 · FY2015 · CA · contact PI
Vermont PROSPR Research Center (VPRC)$53,851
U54 · FY2015 · CA · contact PI
Vermont PROSPR Research Center (VPRC)$1,167,472
U54 · FY2014 · CA · contact PI
Vermont Screening Process Documentation Unit$504,826
U54 · FY2014 · CA · contact PI
Behaviors, Chronic Disease, and Quality of Life After Ductal Carcinoma in Situ$195,203
P20 · FY2014 · GM · contact PI
Vermont Administrative Core$153,914
U54 · FY2014 · CA · contact PI
Breast density and collagen alignment as predictors of DClS disease-free survival$110,317
U54 · FY2014 · CA · contact PI
Vermont PROSPR Research Center (VPRC)$53,851
U54 · FY2014 · CA · contact PI
Vermont PROSPR Research Center (VPRC)$1,150,391
U54 · FY2013 · CA · contact PI
Vermont Screening Process Documentation Unit$600,523
U54 · FY2013 · CA · contact PI
Behaviors, Chronic Disease, and Quality of Life After Ductal Carcinoma in Situ$245,434
P20 · FY2013 · GM · contact PI
Vermont Administrative Core$173,896
U54 · FY2013 · CA · contact PI
Breast density and collagen alignment as predictors of DClS disease-free survival$126,603
U54 · FY2013 · CA · contact PI
Vermont PROSPR Research Center (VPRC)$944,888
U54 · FY2012 · CA · contact PI
Vermont Screening Process Documentation Unit$434,007
U54 · FY2012 · CA · contact PI
Vermont Administrative Core$131,631
U54 · FY2012 · CA · contact PI
Breast density and collagen alignment as predictors of DClS disease-free survival$120,508
U54 · FY2012 · CA · contact PI
Vermont PROSPR Research Center (VPRC)$1,293,911
U54 · FY2011 · CA · contact PI
Vermont Screening Process Documentation Unit$546,473
U54 · FY2011 · CA · contact PI
Breast density and collagen alignment as predictors of DClS disease-free survival$135,514
U54 · FY2011 · CA · contact PI